𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer

✍ Scribed by Jan H. Beumer; Jeany M. Rademaker-Lakhai; Hilde Rosing; Michel J. X. Hillebrand; Tessa M. Bosch; Luis Lopez-Lazaro; Jan H. M. Schellens; Jos H. Beijnen


Book ID
105992504
Publisher
Springer
Year
2006
Tongue
English
Weight
521 KB
Volume
59
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Extreme sensitivity to Yondelis® (Trabec
✍ Victoria Moneo; Beatriz G. Serelde; Jesús Fominaya; Juan F.M. Leal; Carmen Blanc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

## Abstract Yondelis® (Trabectedin, ET‐743) is a marine anticancer agent currently in Phase II/III development in patients with advanced pretreated soft tissue sarcoma. In the present study, we generated a panel of low passaged tumor cell lines from samples explanted from chemonaive sarcoma patient